Exclusive: Blood stem cell therapy maker Garuda gets new CEO, adds $47Mnews2024-11-01T12:55:10+00:00November 1st, 2024|Endpoints News|
Baxter pulls IV products out of China to shift supply to the USnews2024-11-01T11:59:38+00:00November 1st, 2024|Endpoints News|
Essa’s shares tank as it looks for options after abandoning prostate cancer drugnews2024-11-01T11:06:19+00:00November 1st, 2024|Endpoints News|
Biogen brings in medical chief as CFO plans retirement; MacroGenics CEO announces departurenews2024-11-01T11:00:29+00:00November 1st, 2024|Endpoints News|
Q&A with Obesity Society’s CEO as the field prepares for next-gen medsnews2024-11-01T11:00:10+00:00November 1st, 2024|Endpoints News|
FDA adcomm votes against Lexicon’s type 1 diabetes and CKD drugnews2024-11-01T03:07:17+00:00November 1st, 2024|Endpoints News|
Teva fined €462.6M over Copaxone patent and competition allegationsnews2024-10-31T19:25:03+00:00October 31st, 2024|Endpoints News|
UCB’s anti-tau Alzheimer’s program fails Phase 2 primary endpoint, but highlights positive secondariesnews2024-10-31T19:24:55+00:00October 31st, 2024|Endpoints News|
Federal court backs FDA approval of Jazz sleep drug competitornews2024-10-31T19:16:47+00:00October 31st, 2024|Endpoints News|
Regeneron prepares to compete with Eylea biosimilar from Amgennews2024-10-31T18:46:31+00:00October 31st, 2024|Endpoints News|
